Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Ideaya Biosciences Inc (NASDAQ: IDYA) was $27.19 for the day, down -2.09% from the previous closing price of $27.77. In other words, the price has decreased by -$2.09 from its previous closing price. On the day, 0.7 million shares were traded. IDYA stock price reached its highest trading level at $28.3 during the session, while it also had its lowest trading level at $26.99.
Ratios:
Our analysis of IDYA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 22.93 and its Current Ratio is at 22.93. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stephens on November 18, 2024, initiated with a Overweight rating and assigned the stock a target price of $51.
On November 05, 2024, Leerink Partners Downgraded its rating to Market Perform which previously was Outperform but kept the price unchanged to $27.
On October 24, 2024, UBS started tracking the stock assigning a Buy rating and target price of $50.UBS initiated its Buy rating on October 24, 2024, with a $50 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 26 ’24 when Jason Throne bought 75,000 shares for $40.22 per share.
WHITE MICHAEL ANTHONY sold 28,500 shares of IDYA for $1,032,884 on May 29 ’24. The Chief Scientific Officer now owns 0 shares after completing the transaction at $36.24 per share. On May 15 ’24, another insider, Hata Yujiro S, who serves as the President and CEO of the company, sold 83,856 shares for $42.90 each. As a result, the insider received 3,597,756 and left with 677,887 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IDYA now has a Market Capitalization of 2350080768 and an Enterprise Value of 1448847616. For the stock, the TTM Price-to-Sale (P/S) ratio is 599.51 while its Price-to-Book (P/B) ratio in mrq is 1.99. Its current Enterprise Value per Revenue stands at 369.416 whereas that against EBITDA is -6.517.
Stock Price History:
Over the past 52 weeks, IDYA has reached a high of $47.74, while it has fallen to a 52-week low of $25.20. The 50-Day Moving Average of the stock is -6.21%, while the 200-Day Moving Average is calculated to be -26.34%.
Shares Statistics:
IDYA traded an average of 899.02K shares per day over the past three months and 914940 shares per day over the past ten days. A total of 86.36M shares are outstanding, with a floating share count of 77.21M. Insiders hold about 10.67% of the company’s shares, while institutions hold 99.54% stake in the company. Shares short for IDYA as of 1732838400 were 8934689 with a Short Ratio of 9.94, compared to 1730332800 on 9306160. Therefore, it implies a Short% of Shares Outstanding of 8934689 and a Short% of Float of 11.5200005.
